BR112012000095A2 - método de tratamento ou prevenção de ponv ou pdnv - Google Patents

método de tratamento ou prevenção de ponv ou pdnv

Info

Publication number
BR112012000095A2
BR112012000095A2 BR112012000095A BR112012000095A BR112012000095A2 BR 112012000095 A2 BR112012000095 A2 BR 112012000095A2 BR 112012000095 A BR112012000095 A BR 112012000095A BR 112012000095 A BR112012000095 A BR 112012000095A BR 112012000095 A2 BR112012000095 A2 BR 112012000095A2
Authority
BR
Brazil
Prior art keywords
pdnv
ponv
treatment
prevention method
prevention
Prior art date
Application number
BR112012000095A
Other languages
English (en)
Portuguese (pt)
Inventor
M Venkatesh Gopi
Thieroff-Ekerdt Ruth
Perrett Stephen
Original Assignee
Aptalis Pharmatech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aptalis Pharmatech Inc filed Critical Aptalis Pharmatech Inc
Publication of BR112012000095A2 publication Critical patent/BR112012000095A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112012000095A 2009-07-06 2010-07-02 método de tratamento ou prevenção de ponv ou pdnv BR112012000095A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22321809P 2009-07-06 2009-07-06
US12/688,493 US20110003005A1 (en) 2009-07-06 2010-01-15 Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
PCT/US2010/040868 WO2011005671A1 (en) 2009-07-06 2010-07-02 Methods of treating pdnv and ponv with extended release ondansetron compositions

Publications (1)

Publication Number Publication Date
BR112012000095A2 true BR112012000095A2 (pt) 2017-06-13

Family

ID=43412803

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012000095A BR112012000095A2 (pt) 2009-07-06 2010-07-02 método de tratamento ou prevenção de ponv ou pdnv

Country Status (8)

Country Link
US (1) US20110003005A1 (enExample)
EP (1) EP2451276A4 (enExample)
JP (1) JP2012532194A (enExample)
AR (1) AR077394A1 (enExample)
BR (1) BR112012000095A2 (enExample)
TW (1) TW201105657A (enExample)
UY (1) UY32767A (enExample)
WO (1) WO2011005671A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2506714A4 (en) * 2009-11-30 2013-07-03 Aptalis Pharmatech Inc MOUTH ONDANSETRON TABLET COMPOSITIONS TO PREVENT EVIL AND CRUSH
DK2605655T3 (en) 2010-08-19 2019-02-04 Buck Institute For Age Res METHODS OF TREATING SMALL COGNITIVE DISABILITY (MCI) AND RELATED DISORDERS
WO2013123426A1 (en) * 2012-02-18 2013-08-22 Buck Institute For Research On Aging Formulations and methods for the treatment or prophylaxis of pre-mci and/or pre-alzheimer's conditions
US10071088B2 (en) * 2012-06-26 2018-09-11 Precondit, Llc Anti-nausea drug combinations
US9636305B2 (en) * 2013-03-14 2017-05-02 Redhill Biopharma Ltd. Antiemetic extended release solid dosage forms
CA2919892C (en) 2013-08-12 2019-06-18 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
JP6461186B2 (ja) 2014-03-11 2019-01-30 レッド ヒル バイオファーマ リミテッドＲｅｄＨｉｌｌ Ｂｉｏｐｈａｒｍａ Ｌｔｄ． 悪心、嘔吐または下痢の症状を処置するためのオンダンセトロン徐放固形製剤
DK3169315T3 (da) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
EP3209282A4 (en) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
GB201618425D0 (en) * 2016-11-01 2016-12-14 Acacia Pharma Ltd method
GB201702250D0 (en) 2017-02-10 2017-03-29 Acacia Pharma Ltd Method

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3634584A (en) * 1969-02-13 1972-01-11 American Home Prod Sustained action dosage form
GB1468172A (en) * 1973-03-28 1977-03-23 Benzon As Alfred Oral drug preparations
US3954959A (en) * 1973-03-28 1976-05-04 A/S Alfred Benzon Oral drug preparations
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
DD146547A5 (de) * 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
CH647676A5 (fr) * 1978-12-22 1985-02-15 Donald E Panoz Formes galeniques a usage oral, a liberation programmee et leurs procedes de preparation.
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
DE3124090A1 (de) * 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
DE3126703A1 (de) * 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
DE3237575A1 (de) * 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
IE55745B1 (en) * 1983-04-06 1991-01-02 Elan Corp Plc Sustained absorption pharmaceutical composition
IE56459B1 (en) * 1983-12-21 1991-08-14 Elan Corp Ltd Controlled absorption pharmaceutical formulation
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
US4894240A (en) * 1983-12-22 1990-01-16 Elan Corporation Plc Controlled absorption diltiazem formulation for once-daily administration
EP0225085A1 (en) * 1985-11-13 1987-06-10 ELAN CORPORATION, Plc Controlled absorption pharmaceutical formulation
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
IE58401B1 (en) * 1986-06-20 1993-09-08 Elan Corp Plc Controlled absorption pharmaceutical composition
DE3627423A1 (de) * 1986-08-13 1988-02-18 Thomae Gmbh Dr K Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung
AU2016992A (en) * 1991-05-20 1992-12-30 Marion Laboratories, Inc. Multi-layered controlled release formulation
US5464632C1 (en) * 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US5840329A (en) * 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
DE69901938T3 (de) * 1998-03-06 2012-08-02 Aptalis Pharma S.R.L. Schnell zerfallende tablette
US6602521B1 (en) * 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
HU230454B1 (hu) * 1998-11-02 2016-07-28 Alkermes Pharma Ireland Limited Metilfenidátot tartalmazó módosított felszabadulású sokszemcsés készítmény
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6936275B2 (en) * 1999-12-20 2005-08-30 Scolr, Inc. Amino acid modulated extended release dosage form
JP2004508278A (ja) * 2000-01-20 2004-03-18 デルシス　ファーマシューティカル　コーポレイション 多段薬物投与形態
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6500457B1 (en) * 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
WO2003000169A1 (fr) * 2001-06-20 2003-01-03 Takeda Chemical Industries, Ltd. Procede de fabrication de comprimes
DE10149674A1 (de) * 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
US20040019096A1 (en) * 2001-10-23 2004-01-29 Vlassios Andronis Novel formulations of carvedilol
US6663888B2 (en) * 2001-12-14 2003-12-16 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
MY143789A (en) * 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting
US20040265375A1 (en) * 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
US8545881B2 (en) * 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
US9050249B2 (en) * 2004-04-30 2015-06-09 Astellas Pharma Inc. Oral pharmaceutical compositions in timed-release particle form and fast-disintegrating tablets containing this composition
US20060280795A1 (en) * 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
CA2635313C (en) * 2005-12-29 2013-12-31 Osmotica Corp. Triple combination release multi-layered tablet
KR20140088230A (ko) * 2006-01-27 2014-07-09 앱탈리스 파마테크, 인코포레이티드 약 염기성 약물과 유기산을 포함하는 약물 전달 시스템
AU2007211091B8 (en) * 2006-01-27 2013-08-29 Adare Pharmaceuticals, Inc. Drug delivery systems comprising weakly basic selective serotonin 5-HT3 blocking agent and organic acids
NZ576237A (en) * 2006-10-24 2011-12-22 Helsinn Healthcare Sa Soft capsules comprising palonosetron hydrochloride having improved stability and bioavailability
US8133506B2 (en) * 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids

Also Published As

Publication number Publication date
WO2011005671A1 (en) 2011-01-13
UY32767A (es) 2010-12-31
TW201105657A (en) 2011-02-16
JP2012532194A (ja) 2012-12-13
AR077394A1 (es) 2011-08-24
EP2451276A1 (en) 2012-05-16
EP2451276A4 (en) 2012-12-19
US20110003005A1 (en) 2011-01-06

Similar Documents

Publication Publication Date Title
BR112012000095A2 (pt) método de tratamento ou prevenção de ponv ou pdnv
BRPI0910854A2 (pt) métodos de tratamento
PT2640375T (pt) Método de tratamento da nefropatia induzida por contraste
BR112012005594A2 (pt) tratamento de câncer
BRPI0920104A2 (pt) tratamento de soluções ou de águas residuais
BRPI1013317A2 (pt) método de cimentação
BRPI1007477A2 (pt) método, e, composição de tratamento de poço
BRPI0910259A2 (pt) métodos de tratamento de inflamação
BRPI0906141A2 (pt) sistema de tratamento de pressão reduzida
BRPI0810206A2 (pt) Método de tratar câncer
BRPI0919748A2 (pt) dipositivo de tratamento
BRPI0907135A2 (pt) Processos de tratamento de dor crônica
BRPI1012605A2 (pt) método de limpeza
IL212348A0 (en) Treatment method
PT3412687T (pt) Métodos de tratamento de dlbcl
BRPI0917575A2 (pt) métodos de tratamento de talassemia
BR112013012485A2 (pt) método de tratamento com inibidor braf
IL219715A (en) Sewage treatment apparatus
EP2391391A4 (en) STERILIZATION PROCESS
EP2435825A4 (en) METHODS OF TREATING DISEASES
BRPI0920140A2 (pt) método de floculação
BR112012008166A2 (pt) método de tratamento de água e floculante de tratamento de água
EP2448627A4 (en) SAFETY CATHETER
BR112013022820A2 (pt) método de tratamento
BRPI0916079A2 (pt) tratamento de água marinha residual

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]